The implementation of cardioprotection with nicorandil from periprocedural damage during elective percutaneous coronary interventions in patients with stable coronary heart disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The purpose of the study is to demonstrate such an effect of the nicorandil like the pharmacological preconditioning in patients with stable coronary heart disease during elective percutaneous coronary intervention.

Full Text

Restricted Access

About the authors

R. Gostishchev

A.L. Myasnikov Institute of Clinical Cardiology National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

Email: gostiroman@gmail.com

G. Soboleva

A.L. Myasnikov Institute of Clinical Cardiology National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

A. Samko

A.L. Myasnikov Institute of Clinical Cardiology National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

A. Minasyan

A.L. Myasnikov Institute of Clinical Cardiology National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation

References

  1. Fox K., Garcia M., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology // Eur. Heart J. - 2006; 27(11): 1341-81.
  2. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д. от имени участников исследования КВАЗАР. Сравнительная оценка антиангинальной эффективности и безопасности препарата никорандил на фоне базисной терапии ß-адреноблокаторами у больных ишемической болезнью сердца со стабильной стенокардией // Кардиология. 2016; 10: 30-4. DOI: http://dx.doi.org/10.18565/cardio.2016.10.30-34.
  3. IONA Study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial // Lancet. - 2002; 359 (9314): 1269-75.
  4. Гостищев Р.В., Соболева Г.Н., Самко А.Н. и др. Фармакологическое пре-кондиционирование. В фокусе - никорандил // Рос. кардиол. журн. - 2017; 8: 114-21. doi: 10.15829/1560-4071-2017-8-114-121.
  5. Ishii H., Ichimiya S., Kanashiro M. et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction // Circulation. - 2005; 112 (9): 1284-8.
  6. Ono H., Osanai T., Ishizaka H. et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation // Am. Heart J. - 2004; 148 (4): E15.
  7. Ota S., Nishikawa H., Takeuchi M. et al. Impact of Nicorandil to Prevent Reperfusion Injury in Patients With Acute Myocardial Infarction Sigmart Multicenter Angioplasty Revascularization Trial (SMART) // Circ. J. - 2006; 70: 1099-104.
  8. Lee H., An S., Choi J. et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction // Circ. J. - 2008; 72 (9): 1425-9.
  9. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. - 2007; 48: 1676-82.
  10. Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. - 2012; 59 (1): 14-21. doi: 10.1016/j.jjcc.2011.08.001.
  11. Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anatolian J. Cardiol. - 2015; 15: 125-31.
  12. Kawai Y., Hisamatsu K., Matsubara H. et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon // Eur. Heart J. - 2009; 30 (7): 765-72. doi: 10.1093/eurheartj/ehp077.
  13. Isono T., Kamihata H., Sutani Y. et al. Nicorandil suppressed myocardial injury after percutaneous coronary intervention // Int. J. Cardiol. - 2008; 123 (2): 123-8.
  14. Hirohata A., Yamamoto K., Hirose E. et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study // Eur. Int. - 2014; 9 (9): 1050-6. doi: 10.4244/EIJV9I9A178.
  15. Nallamothu B., Chetcuti S., Mukherjee D. et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention // Am. J. Cardiol. -2003; 91: 1272-74.
  16. Kini A., Lee P., Marmur J. et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality // Am. J. Cardiol. - 2004; 93: 18-23.
  17. Cavallini C., Savonitto S., Violini R. et al. Impact of the elevation of biochemical markers of myocardial damage on long-103term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study // Eur. Heart J. - 2005; 26: 1494-8.
  18. Thygesen K., Alpert J., Jaffe A. et al. Third universal definition of myocardial infarction // Eur. Heart J. - 2012; 33: 2551-67.
  19. Миронова О.Ю. Клиническое и прогностическое значение инфаркта миокарда, развившегося в результате проведения плановой коронарной ангиопластики у пациентов со стабильной ишемической болезнью сердца. Дис.. канд. мед. наук. М., 2015.
  20. Su Q., Li L., Zhao J. et al. Effects of nicorandil on PI3K/Akt signaling pathway and its anti- apoptotic mechanisms in coronary microembolization in rats // Oncotarget. - 2017; 8: 99347-58.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Russkiy Vrach Publishing House